Diclofenac acts as an antagonist at peroxisome proliferator-activated receptor gamma (PPARG), and is used both to reduce inflammation and as an analgesic. PPARG is a nuclear receptor, and regulates fatty acid and glucose metabolism. Its activation is believed to be responsible for inhibiting the growth of various cancers.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NEC830:

1. Heather L. Handl, Josef Vagner, Henry I. Yamamura, Victor J. Hruby, Robert J. Gillies, Development of a lanthanide-based assay for detection of receptor–ligand interactions at the δ-opioid receptor, In Analytical Biochemistry, Volume 343, Issue 2, 2005, Pages 299-307.